Reducing immune reactions to gene delivery using engineered materials
Official title: Mitigating the Immunogenicity of Engineered Aav Gene Delivery Vectors by Biomaterial-Driven Immunosuppression
Funded at Cornell University · NIH-10741139 · Data updated 2026-11-12
This study is looking at ways to make gene therapy using adeno-associated viruses (AAV) work better by reducing the body's immune response, so patients with chronic and genetic diseases can receive more effective and long-lasting treatments over time.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $435,412 |
| NIH project number | 1R21EB033963-01A1 |
| Project ID | NIH-10741139 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with chronic or genetic diseases that may benefit from repeated gene therapy treatments.
✕Less likely to help
Patients who do not have chronic or genetic diseases or those who are not candidates for gene therapy may not benefit from this research.
What this research studies
This research focuses on improving the effectiveness of gene delivery using adeno-associated viruses (AAV) by reducing the immune response that can limit their use. The approach involves creating a special material that can suppress the immune system's reaction to these viral vectors, allowing for repeated treatments over time. By engineering a specific peptide that mimics natural substances in the body, the researchers aim to enhance the durability and effectiveness of AAV gene therapies for chronic and genetic diseases. This could potentially lead to better long-term outcomes for patients requiring ongoing treatment.
Why it matters
Potential benefit: If successful, this research could enable more effective and longer-lasting gene therapies for patients with chronic and genetic diseases.
How similar studies have gone: Previous research has shown promise in using biomaterials to modulate immune responses, suggesting that this approach could be effective.
Where this research is happening
-
Cornell University
Ithaca, United States Active
Researchers
- Principal investigator: Jiang, Shaoyi — Cornell University
- Study coordinator: Jiang, Shaoyi
Related research
Other NIH-funded projects on the same topics.
-
Vascular signals from brain blood vessels influence immune-suppressing cells in glioblastoma
This grant explores how blood vessel cells in glioblastoma shape immune cells to help the tumor grow, with the aim of making immunotherapies work better for patients.
-
Vascularized niche with local immune protection to transplant insulin-producing cells for Type 1 diabetes
A new approach aims to transplant insulin-producing cells inside a vascularized pocket with local drug delivery to keep them alive and functioning without full-body immune suppression.
-
AHR-driven immunosuppression in glioblastoma and new therapeutic targets
A personalized cancer study aims to understand why glioblastoma suppresses the immune system and to find ways to boost anti-tumor immunity in patients with this brain tumor.
-
Fibroblast-made GABA fuels PDAC immune suppression
In people with pancreatic cancer, this study explores how a specific cell type in the tumor environment uses a brain-like chemical (GABA) to dampen immune attack against the cancer.
-
Biomarker-guided reduction of immunosuppression after liver transplant
A multicenter trial tests whether using blood biomarkers to guide tapering of immunosuppression in adults with liver transplants can keep people healthy while lowering drug exposure.
-
Understanding and Overcoming T cell Immunosuppression in Glioblastoma (GBM)
A large research program is looking at how glioblastoma tumors weaken immune responses and how to boost immune cells to fight GBM.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.